In the light of this knowledge, it was perhaps not an unexpected finding that the mere presence of IGF-1 in serum, or the level of IGF-1R on the surface of tumor cells, has not been found to be a useful biomarker for tumor incidence or progression (46–48). Here, IGF1 is linked to neoplasm.